WellCare denied your IVIG? What to do next

Why WellCare (Centene) denies IVIG and immunoglobulin

WellCare is Centene's Medicare Advantage and Part D brand, with a large footprint in MA-PD and standalone Part D plans. Because WellCare operates under Medicare, appeals follow the federal 5-level Medicare Advantage and Part D appeal ladders rather than state external-review programs.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

The law that controls this appeal

Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).

What WellCare (Centene) denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
Continuation after the initial authorization period when response is not documented
Dose or frequency above the policy's stated range
Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical WellCare (Centene) IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Diagnosis not on the plan's list of covered indications
Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
No documented failure of first-line therapy where the policy requires it
Response to prior IVIG cycles not documented in measurable terms
Plan classifies the use as experimental or investigational

The WellCare (Centene) appeal process

Appeal levels: Federal Medicare 5-level ladder: plan reconsideration → IRE (MAXIMUS) → ALJ → Medicare Appeals Council → federal district court. Fast-track QIO review for inpatient and post-acute terminations.

Carrier timing: 60 days between most levels. Expedited urgent decisions in 72 hours. ALJ requires the amount in controversy to exceed the annual threshold ($200+ in 2026).

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about WellCare (Centene): WellCare cases benefit from early escalation. We do not stop at the plan-level denial, the IRE and ALJ levels are where complex reversals happen.

Common WellCare (Centene) denial patterns for IVIG and immunoglobulin

Plan reconsideration is just the first step. WellCare's plan-level reconsideration is level 1. A meaningful share of denials reverse only at level 2 (MAXIMUS IRE) or higher. Members who stop at the plan denial often leave a winnable case on the table.
Part D formulary and tiering exceptions. WellCare Part D denials route through coverage determination → redetermination → IRE → ALJ. Formulary exception requests with prescriber clinical support are the standard entry point for non-formulary drugs.
Skilled nursing and home health terminations. WellCare MA plans, like other MA carriers, have been subject to CMS scrutiny on early termination of post-acute care. Expedited fast-track appeals through the Beneficiary and Family Centered Care QIO are available when termination notices are issued.

How to win your WellCare (Centene) IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against WellCare (Centene), that strategy rides on this procedural spine:

Procedural-rights anchor. Every WellCare (Centene) denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
Criteria-disclosure demand. WellCare (Centene) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
Treating-provider attestation. A letter from the treating physician addressing each criterion in WellCare (Centene)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your WellCare (Centene) IVIG and immunoglobulin appeal

The denial letter naming the criterion or policy applied
Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
Record of prior therapies and outcomes
Infusion records showing dose, frequency, and documented response
The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

WellCare (Centene) IVIG and immunoglobulin appeals: frequently asked questions

WellCare (Centene) says IVIG is experimental for my condition. Can that be appealed?

Yes. 'Experimental or investigational' determinations are appealable internally and are expressly within the scope of external review. The strongest appeals identify the published guideline or evidence the specialist relies on and show it directly.

My infusions are scheduled this week. What do I do first?

Ask for an expedited appeal in writing and have the prescriber confirm that delay could seriously jeopardize health. Expedited decisions are due within 72 hours.

WellCare (Centene) approved IVIG before. Why is it denied now?

Continuation reviews look for measurable response. If the record only says 'doing well', the plan may treat that as no evidence. The specialist's note should record the objective measures the policy asks for.

Does WellCare (Centene) have to tell me which policy it used?

For employer and ACA plans, yes: the internal rule, guideline, or protocol relied on must be provided free on request. Ask for it by name in the appeal.

What Apellica does for WellCare (Centene) IVIG and immunoglobulin appeals

We file appeals against WellCare (Centene) specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for WellCare (Centene) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your WellCare (Centene) IVIG and immunoglobulin appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

WellCare (Centene) denied your IVIG and immunoglobulin? Here is what to do next